Patents by Inventor Pamela Nero

Pamela Nero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION
    Publication number: 20120022133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of diseases associated with expression of cholesteryl ester transfer protein are provided.
    Type: Application
    Filed: April 7, 2011
    Publication date: January 26, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Pamela Nero, Edward Wancewicz
  • Antisense modulation of MEKK4 expression
    Publication number: 20060019920
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: July 11, 2005
    Publication date: January 26, 2006
    Inventors: C. Bennett, Susan Freier, Brett Monia, Nicholas Dean, Hong Zhang, Robert McKay, Donna Ward, William Gaarde, Jacqueline Wyatt, Andrew Watt, Rosanne Crooke, Mark Graham, Pamela Nero, Kenneth Dobie, Alexander Borchers, Eric Marcusson, Mark Roach
  • Antisense modulation of p70 S6 kinase expression
    Publication number: 20050267063
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with expression of p70 S6 kinase are provided.
    Type: Application
    Filed: April 27, 2005
    Publication date: December 1, 2005
    Inventors: C. Bennett, Brett Monia, Susan Freier, Brenda Baker, William Gaarde, Erich Koller, Susan Murray, Andrew Watt, Jacqueline Wyatt, Pamela Nero, Mark Roach, Lex Cowsert, Kenneth Dobie
  • Antisense modulation of thyroid hormone receptor interactor 6 expression
    Publication number: 20050222073
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding thyroid hormone receptor interactor 6. Methods of using these compounds for modulation of thyroid hormone receptor interactor 6 expression and for treatment of diseases associated with expression of thyroid hormone receptor interactor 6 are provided.
    Type: Application
    Filed: March 2, 2005
    Publication date: October 6, 2005
    Inventors: C. Bennett, Brett Monia, Rosanne Crooke, Mark Graham, Susan Freier, Pamela Nero, Edward Wancewicz, Nicholas Dean, Lex Cowsert, Kenneth Dobie
  • Antisense modulation of cholesteryl ester transfer protein expression
    Publication number: 20050137160
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of diseases associated with expression of cholesteryl ester transfer protein are provided.
    Type: Application
    Filed: January 7, 2005
    Publication date: June 23, 2005
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Rosanne Crooke, Mark Graham, Pamela Nero, Edward Wancewicz
  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Patent number: 6809193
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: October 26, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela Nero, William A. Gaarde
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Publication number: 20040171566
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: August 15, 2003
    Publication date: September 2, 2004
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay, Wai Shiu Fred Wong
  • Antisense modulation of MDM2 expression
    Publication number: 20030203862
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Application
    Filed: December 4, 2001
    Publication date: October 30, 2003
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Erich Koller, Ming Yi Chiang, Muthiah Manoharan
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Publication number: 20030176383
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Application
    Filed: September 9, 2002
    Publication date: September 18, 2003
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Antisense modulation of cholesteryl ester transfer protein expression
    Publication number: 20030092647
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of diseases associated with expression of cholesteryl ester transfer protein are provided.
    Type: Application
    Filed: August 8, 2001
    Publication date: May 15, 2003
    Inventors: Rosanne M. Crooke, Mark J. Graham, Pamela Nero, Edward Wancewicz
  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Publication number: 20030004120
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Application
    Filed: January 31, 2001
    Publication date: January 2, 2003
    Inventors: Robert McKay, Nicholas M. Dean, Brett P. Monia, Pamela Nero, William A. Gaarde
  • Antisense oligonucleotide modulation of human MDM2 expression
    Publication number: 20020151511
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Application
    Filed: May 9, 2001
    Publication date: October 17, 2002
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia
  • Antisense modulation of p38 mitogen activated protein kinase expression
    Patent number: 6448079
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela Nero, Robert McKay
  • Antisense modulation of human MDM2 expression
    Publication number: 20010016575
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Application
    Filed: January 2, 2001
    Publication date: August 23, 2001
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert
  • Antisense oligonucleotide modulation of human mdm2 expression
    Patent number: 6238921
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Grant
    Filed: March 26, 1998
    Date of Patent: May 29, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia
  • Antisense modulation of human mdm2 expression
    Patent number: 6184212
    Abstract: Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: February 6, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Loren J. Miraglia, Pamela Nero, Mark J. Graham, Brett P. Monia, Lex M. Cowsert